BDTX

In the past six months, Black Diamond Therapeutics' stock (BDTX) has decreased by 9.68%. On May 22, 2026, the stock experienced its largest daily decline of 35.8% despite positive Phase 2 results for silevertinib in frontline NSCLC patients, attributed to investor concerns about the early nature of the data and competitive fears. Conversely, on May 19, 2026, the stock saw a positive movement of +16.28%. Other significant events include the reporting of Second Quarter 2026 Financial Results and a corporate update on August 5, 2026, and the announcement of participation in the H.C. Wainwright 28th Annual Global Investment Conference on September 2, 2026. Additional stock movements in the past six months include a +3.28% change on April 21, 2026, a -3.55% change on May 7, 2026, a +1.83% change on March 16, 2026, and a -5.35% change on March 2, 2026.